Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GRN163L · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 3+3 cohort dose escalation |
| open label | OTHER | Sequential dose cohort, open label, escalation trial evaluating one infusion duration of 2 hours |
| Name | Type | Description |
|---|---|---|
| GRN163L | DRUG | 25% dose escalation infused over 2 hours weekly |
Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the breast with measurable locally recurrent or metastatic disease * May have had one prior non-taxane chemotherapy regimen for metastatic disease * If HER2 positive, must have had prior treatment with trastuzumab (He...
Top 20 of 92 competitors
GRN163L is an investigational small molecule being studied for chronic lymphoproliferative diseases and breast cancer. It has been evaluated in Phase 1 clinical trials for these oncology indications.
GRN163L is being developed by Geron Corporation, a biopharmaceutical company traded on NASDAQ under the ticker symbol GERN.
GRN163L is in Phase 1 clinical development. It has completed Phase 1 trials, and it remains investigational, meaning it is not yet approved by regulatory authorities.
GRN163L has been studied in two completed Phase 1 trials. One trial, NCT00124189, enrolled 48 patients with chronic lymphoproliferative diseases. Another trial, NCT00732056, enrolled 24 patients with locally recurrent or metastatic breast cancer, combining GRN163L with paclitaxel and bevacizumab.
No, GRN163L is not the same as imetelstat. GRN163L is a distinct investigational small molecule developed by Geron Corporation for chronic lymphoproliferative diseases and breast cancer.